Search

BACKGROUND: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 (ACE2, the SARS-CoV-2 receptor) and of immunoregulatory genes in normal lung tissues from patients with non-small cell lung cancer (NSCLC). METHODS: This study used the transcriptomic and the clinical data for NSCLC patients generated during the CHEMORES study [n = 123 primary resected (early-stage) NSCLC] and the WINTHER clinical trial (n = 32 metastatic NSCLC). RESULTS: We identified patient subgroups with high and low ACE2 expression (p = 1.55 × 10-19) in normal lung tissue, presumed to be at higher and lower risk, respectively, of developing severe COVID-19 should they become infected. ACE2 transcript expression in normal lung tissues (but not in tumor tissue) of patients with NSCLC was higher in individuals with more advanced disease. High-ACE2 expressors had significantly higher levels of CD8+ cytotoxic T lymphocytes and natural killer cells but with presumably impaired function by high Thymocyte Selection-Associated High Mobility Group Box Protein TOX (TOX) expression. In addition, immune checkpoint-related molecules - PD-L1, CTLA-4, PD-1, and TIGIT - are more highly expressed in normal (but not tumor) lung tissues; these molecules might dampen immune response to either viruses or cancer. Importantly, however, high inducible T-cell co-stimulator (ICOS), which can amplify immune and cytokine reactivity, significantly correlated with high ACE2 expression in univariable analysis of normal lung (but not lung tumor tissue). CONCLUSIONS: We report a normal lung immune-tolerant state that may explain a potential comorbidity risk between two diseases - NSCLC and susceptibility to COVID-19 pneumonia. Further, a NSCLC patient subgroup has normal lung tissue expressing high ACE2 and high ICOS transcripts, the latter potentially promoting a hyperimmune response, a

Uncertainty analysis is a key element of sound techno-economic analysis (TEA) of CO2 Capture and Storage (CCS) technologies and systems, and in the communication of TEA results. Many CCS technologies are relatively novel, with only few large-scale projects constructed and in operation to date. Therefore, uncertainties in technology performance and costs are often substantial, making it imperative that they be characterized and reported. Although uncertainty analysis itself is not novel, with some methods already frequently used by the CCS TEA community, a document that provides a comprehensive overview of methods and approaches, as well as guidance on their selection and use, is still lacking. Given its importance, we seek to fill this gap by providing a critical review of uncertainty analysis methods along with guidance on the selection and use of these methods for CCS TEAs, highlighting good practice and examples from the CCS literature. The paper starts by identifying the different audiences for CCS TEAs, the different modelling approaches available for CCS technology performance and cost analysis, and the different roles that uncertainty analysis may play. It then continues to discuss established, as well as emerging, uncertainty analysis methods and addresses how and when each method is best used, as well as common pitfalls. We argue that the most commonly used method of one-parameter-at-a-time ‘local’ sensitivity analysis may often be a suboptimal choice, and that other approaches may be more suitable or lead to more insight, especially since uncertainty analysis software is becoming more widespread and easier to use. Finally, the paper discusses the benefits of advanced uses of uncertainty analysis in, for instance, the design of CCS experiments or in the design and planning of CCS infrastructure. Sound uncertainty analysis has an important role to play in TEAs of CCS technologies and systems, and there are many opportunities to bring the use of uncertainty a, QC 20200806